• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

India gives Abbott a year to withdraw Xience Alpine stent

September 26, 2017 By Sarah Faulkner

AbbottIndia’s drug pricing authority has given Abbott (NYSE:ABT) a year to pull its Xience Alpine drug-eluting stent from the market, according to an Indian Economic Times report.

The company approached India’s National Pharmaceutical Pricing Authority nearly a month ago looking to withdraw the device, citing price caps set on stents earlier this year.

Abbott first has to issue a public notice withdrawing Alpine, the regulator told ET, which it has not yet done.

The NPPA reportedly said it was “left with no option” but to grant Abbott’s request, since the country’s Dept. of Pharmaceuticals does not allow it to exercise provisions to extend restrictions on companies from discontinuing their stents in India.

The regulatory body pushed back against Abbott’s argument that selling the device in India was not viable after the maximum prices of drug-eluting stents were capped.

“The Authority, accordingly, examined the whole issue and found that the import cost of Alpine brand is less than the ceiling price and adequate margins are there, so the reason of unviability of sales in India is not understandable,” the NPPA said in prepared remarks.

“It was also found that these brands have a sizable market share and its withdrawal will create sudden shortage of stents which will not be in the interest of public health safety.”

The NPPA invoked a public interest clause in regulations, stopping Abbott from withdrawing the device for a year’s time.

According to the rule, Abbott needs to maintain an uninterrupted supply of the Xience Alpine device – equivalent to the average imports for the device between June and August this year. After seven months, the company can start reducing supplies by 15% until it withdraws the product completely.

“The NPPA has accepted our application to withdraw our latest drug eluting stent technology Alpine. The ceiling price that has been set unfortunately makes it an unsustainable business to continue to provide Alpine given our cost of manufacture and other associated costs,” an Abbott spokesperson said to ET.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: abbott

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS